Phathom Pharmaceuticals
Biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, with lead product vonoprazan for acid-related disorders.
Location
Florham Park, New Jersey, USA
Founded
2018
Investors
1
Categories
pharmaceuticals, gastroenterology, acid-related-disorders
Notes
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's lead product, vonoprazan, is a potassium-competitive acid blocker (PCAB) that provides faster and more potent acid suppression than traditional proton pump inhibitors (PPIs).
Vonoprazan is FDA-approved and marketed as VOQUEZNA for erosive esophagitis and VOQUEZNA Triple Pak/Dual Pak for H. pylori infection.
Team
- Terrie Curran - Chief Executive Officer
- LinkedIn: linkedin.com/in/terriecurran
- Anthony S. Ford - Chief Financial Officer
Additional Research Findings
- Founded in 2018 in Florham Park, New Jersey
- Listed on NASDAQ (ticker: PHAT)
- Portfolio company of Abingworth
- Lead product vonoprazan (VOQUEZNA) - PCAB mechanism
- Licensed vonoprazan from Takeda for US market
- FDA approved for erosive esophagitis and H. pylori
- Offers faster onset of action than traditional PPIs
- Growing GI-focused commercial business
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |